Real-world US post-FDA approval usage of the Watchman device presented at TCT 2016

(Cardiovascular Research Foundation) Results from the US real-world, post-FDA approval experience of the Watchman device found high procedural success and low complication rates despite implantations by a large percentage of new operators. The Watchman device was approved by the US Food and Drug Administration in March 2015 for left atrial appendage occlusion to reduce the risk of stroke in patients with non-valvular atrial fibrillation.